Articles tagged with: contraceptive

Aug20

An ArcGIS Mapping Tool to Identify MPT Target Populations

Tuesday, 20 August 2019 Written by // Suzanne Ryan-Ibarra, Kyli Gallington, IMPT Secretariat Staff Tags // contraceptive, GIS mapping, HIV, women

In sub-Saharan Africa, adolescent girls and young women are at the highest risk of acquiring HIV. However, as this is a heterogeneous population, the characteristics of these women can vary greatly. A one-size-fits-all approach simply will not work. In order for MPTs to have the greatest impact, approaches must be tailored to the populations where they are most likely to be successful.

Jul22

FROM THE PIPELINE | Fast track to an MPT: Development of a dual-purpose pill containing oral PrEP and an oral contraceptive

Monday, 22 July 2019 Written by // Barbara Friedland Series // From the Pipeline Tags // contraceptive, dual-purpose, pill, Population Council, prevention, women

Imagine if women could take one pill every day and be protected from unintended pregnancy AND HIV? 

And what if this pill was available within several years? 

We believe the fastest route to a contraceptive MPT is to combine two products that are ALREADY ON THE MARKET into a single pill.

A dual-purpose pill has the potential to play an important role in helping women protect themselves against both unintended pregnancy and HIV infection.

The Population Council is working with partners to fast-track development of dual- purpose pill

Nov05

FROM THE PIPELINE | Yaso Therapeutics Yaso-GEL promises to prevent pregnancy and STIs and fill an unmet need in the market

Monday, 05 November 2018 Written by // Mary Weitzel, Barbara North Series // From the Pipeline Tags // contraceptive, STIs, women

We at Yaso Therapeutics are developing a vaginal gel, called Yaso-GEL, that uses a single proprietary drug to prevent pregnancy as well as genital herpes, gonorrhea, and chlamydia. The gel is mucoadhesive, non-irritating, relatively low-cost, and stable. Yaso-GEL aims to be an MPT that can fill the need for non-hormonal contraceptives and protect women from sexually transmitted infections (STIs).

Oct17

FROM THE PIPELINE | Monoclonal antibodies as future MPT products

Wednesday, 17 October 2018 Written by // Kevin Whaley Series // From the Pipeline Tags // contraceptive, HIV, manufacturing, monoclonal antibodies

Monoclonal antibodies are engineered proteins derived from a single parent cell and have been used in a diverse range of therapeutic applications due to their versatility and specificity. At Mapp Biopharmaceutical, Inc., we believe monoclonal antibodies are promising candidates for multipurpose prevention technologies (MPTs) when formulated as topical (e.g., films and rings) or injectable products. Systemic antibodies may have multiple effector functions – like complement binding (CDC) and binding to monocytes (ADCC) – while mucosal mechanisms agglutination and trapping in mucus are less widely discussed, but are crucial for the protection of mucosal surfaces. Systemically and mucosally delivered antibodies have demonstrated efficacy in SHIV prevention studies. In this post, we describe some of the important progress to date on monoclonal antibodies as future MPTs.

Recent Posts

Any thoughts? Contact us to learn more about the submission process.

Share

Spread the word about the promise of MPTs.

Collaborate

We will go further together – join the movement for MPTs.

Contribute

Your financial and in-kind support can help make MPTs a reality.